After urging price concessions for pneumococcal disease vaccines in January and receiving a 20-cent-per-dose discount from Pfizer, Médecins Sans Frontières is sure to be unhappy with GlaxoSmithKline's response.
Last week, international charity Médecins Sans Frontières called on Pfizer to drop its price on pneumococcal vaccine Prevenar 13. The pharma giant responded earlier this week, lopping 20 cents off the per-dose cost through vaccine alliance GAVI. But the way MSF sees it, that's not good enough.
GAVI nets $50M for Merck's Gardasil, GSK's Cervarix
Back in 2012, the GAVI Alliance announced plans to help immunize 30 million girls in 40 countries with HPV vaccines by 2020. Wednesday, the Children's Investment Fund Foundation chipped in toward that goal with a $25 million investment that will be matched through the U.K.'s Department of International Development.
The GAVI Alliance has already saved about 6 million lives through its funding of low-cost immunization for developing countries. And now, it's looking to save 6 million more through 2020.
Glaxo announces 5-year price freeze for post-GAVI countries
GlaxoSmithKline has been a partner of the GAVI Alliance for years, offering some of its vaccines at low cost to help support immunization efforts for children in emerging countries. But now, it's going one step further with a 5-year price freeze on three of its vaccines for countries that graduate from GAVI funding.
Back in November, the GAVI Alliance added inactivated poliovirus vaccines to the list of products it makes available in the world's poorest countries. Now UNICEF is adding its backing, striking a deal with Sanofi to supply the vaccine to GAVI-supported countries for as little as $1 per dose.
GAVI adds support for inactivated polio vaccine
The GAVI Alliance is adding the inactivated poliovirus vaccine (IPV) to the list of products it makes available for routine immunization in the world's 73 poorest countries. GAVI is encouraging countries to co-finance IPV but not making it mandatory.
Indian rotavirus vax set to undercut GSK and Merck
Having committed to offering its rotavirus vaccine--Rotavac--for $1 a dose in 2011, Indian vaccine manufacturer Bharat Biotech has now presented positive Phase III data that compares favorably to currently available rotavirus vaccines.
GlaxoSmithKline, Merck offer GAVI 95% discount on HPV vaccines
GlaxoSmithKline and Merck are slashing the prices of their HPV vaccinations in a deal with the GAVI Alliance, which delivers immunizations to the developing world.
GSK, Merck agree on HPV vax discount with GAVI
Social issues have held back uptake of GlaxoSmithKline and Merck human papillomavirus (HPV) vaccines in the U.S., but globally the problem is more fundamental--the shots cost too much. It is these low-income countries--where 85% of cervical cancer cases occur--that need the vaccines most though.